2seventy bio Announces Additional Data from KarMMa Studies o

Subgroup analysis of outcomes for patients with high-risk relapsed and refractory multiple myeloma from the pivotal Phase 3 KarMMa-3 trial accepted for oral presentation at EHA


Analysis from... | May 11, 2023

Related Keywords

Belgium , University Of Texas , Texas , United States , Chicago , Illinois , Germany , Heidelberg , Baden Wüberg , Leuven , Region Flamande , France , Houston , Melissa Alsina , Steve Bernstein , Bristol Myers Squibb , Michel Delforge , Hemophagocytic Lymphohistiocytosis , Julia Piasecki , Yi Lin , Krina Patel , Salomon Manier , Afshin Mashadi Hossein , Marcs Raab , Nasdaq , European Hematology Association , Md Anderson Cancer Center , Heidelberg University Hospital , Centre Hospitalier Universitaire De Lille , University Of Leuven , Linkedin , Moffitt Cancer Center , Twitter , American Society Of Clinical Oncology , American Society , Clinical Oncology , Annual Meeting , Nicholas Stong , Cancer Center , Mayo Clinic , Profit Share Agreement , Release Syndrome , Macrophage Activation Syndrome , Risk Evaluation , Mitigation Strategy , Igg Secondary Malignancies , Operate Machinery , Prescribing Information , Cautionary Note Regarding Forward Looking , 2seventy Bio , Nc Stock Exchange , News , Information , Press Release , Subgroup , Analysis , F , Outcomes , Or , Patients , Ith , Relapsed , End , Refractory , Multiple , Myeloma , Rom , The , Pivotal , Hase , , Trial , Accepted , Mural , Presentation , T Tsvt Us9013841070 ,